Abbott Laboratories - ABT Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $122.14
  • Forecasted Upside: 12.17%
  • Number of Analysts: 13
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 10 Buy Ratings
  • 0 Strong Buy Ratings
$108.89
▼ -0.22 (-0.20%)

This chart shows the closing price for ABT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Abbott Laboratories Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ABT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ABT

Analyst Price Target is $122.14
▲ +12.17% Upside Potential
This price target is based on 13 analysts offering 12 month price targets for Abbott Laboratories in the last 3 months. The average price target is $122.14, with a high forecast of $141.00 and a low forecast of $103.00. The average price target represents a 12.17% upside from the last price of $108.89.

This chart shows the closing price for ABT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 13 contributing investment analysts is to moderate buy stock in Abbott Laboratories. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 10 buy ratings
  • 3 hold ratings
  • 0 sell ratings
10/23/2022
  • 0 strong buy ratings
  • 10 buy ratings
  • 3 hold ratings
  • 0 sell ratings
1/21/2023
  • 0 strong buy ratings
  • 10 buy ratings
  • 3 hold ratings
  • 0 sell ratings
4/21/2023
  • 0 strong buy ratings
  • 10 buy ratings
  • 3 hold ratings
  • 0 sell ratings
7/20/2023
  • 0 strong buy ratings
  • 10 buy ratings
  • 3 hold ratings
  • 0 sell ratings
10/18/2023
  • 0 strong buy ratings
  • 10 buy ratings
  • 3 hold ratings
  • 0 sell ratings
1/16/2024
  • 0 strong buy ratings
  • 10 buy ratings
  • 3 hold ratings
  • 0 sell ratings
3/16/2024
  • 0 strong buy ratings
  • 10 buy ratings
  • 3 hold ratings
  • 0 sell ratings
4/15/2024

Latest Recommendations

  • 0 strong buy ratings
  • 10 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/4/2024Evercore ISIBoost TargetOutperform ➝ Outperform$120.00 ➝ $125.00Low
4/3/2024CitigroupBoost TargetBuy ➝ Buy$126.00 ➝ $128.00Low
2/14/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$128.00Low
1/26/2024BarclaysBoost TargetOverweight ➝ Overweight$133.00 ➝ $141.00Low
1/25/2024CitigroupBoost TargetBuy ➝ Buy$123.00 ➝ $126.00Low
1/25/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$128.00Low
1/25/2024Raymond JamesBoost TargetOutperform ➝ Outperform$124.00 ➝ $127.00Low
1/11/2024Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$119.00 ➝ $128.00Low
1/3/2024Raymond JamesBoost TargetOutperform ➝ Outperform$110.00 ➝ $124.00Low
12/13/2023Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$116.00 ➝ $121.00Low
10/19/2023UBS GroupLower Target$130.00 ➝ $118.00Low
10/19/2023Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$112.00 ➝ $107.00Low
10/19/2023Raymond JamesLower TargetOutperform ➝ Outperform$123.00 ➝ $110.00Low
10/19/2023Wells Fargo & CompanyLower TargetOverweight ➝ Overweight$136.00 ➝ $116.00Low
10/2/2023Jefferies Financial GroupLower Target$120.00 ➝ $112.00Low
10/2/2023CitigroupLower Target$130.00 ➝ $122.00Low
7/24/2023BarclaysBoost TargetOverweight$127.00 ➝ $132.00Low
7/21/2023Morgan StanleyReiterated RatingEqual Weight ➝ Equal Weight$112.00Low
7/21/2023MizuhoBoost TargetNeutral ➝ Neutral$110.00 ➝ $115.00Low
7/21/2023Wolfe ResearchUpgradeUnderperform ➝ Peer PerformLow
5/30/2023Morgan StanleyDowngradeOverweight ➝ Equal Weight$112.00Low
4/20/2023Raymond JamesBoost Target$116.00 ➝ $123.00Low
4/20/2023Wolfe ResearchLower TargetUnderperform$107.00 ➝ $103.00Low
4/20/2023Sanford C. BernsteinBoost TargetOutperform$132.00 ➝ $133.00Low
4/20/2023JPMorgan Chase & Co.Boost TargetOverweight$118.00 ➝ $122.00Low
4/20/2023UBS GroupBoost TargetBuy$117.00 ➝ $130.00Low
4/20/2023BarclaysBoost TargetOverweight$125.00 ➝ $127.00Low
4/19/2023CitigroupBoost TargetBuy$125.00 ➝ $130.00Low
4/17/2023BTIG ResearchBoost TargetBuy$125.00 ➝ $130.00Low
4/17/2023Raymond JamesLower TargetOutperform$123.00 ➝ $116.00Low
4/5/2023Wells Fargo & CompanyLower TargetOverweight$140.00 ➝ $136.00Low
3/31/2023SVB LeerinkBoost TargetMarket Perform$90.00 ➝ $102.00Low
3/30/2023Bank of AmericaLower Target$125.00 ➝ $115.00Low
3/28/2023UBS GroupInitiated CoverageBuy$117.00Low
1/27/2023BarclaysBoost TargetOverweight$122.00 ➝ $125.00Low
1/26/2023Stifel NicolausBoost TargetBuy$110.00 ➝ $125.00Low
1/26/2023Raymond JamesBoost TargetOutperform$109.00 ➝ $123.00Low
1/26/2023Sanford C. BernsteinBoost TargetOutperform$125.00 ➝ $132.00Low
1/24/2023MizuhoBoost TargetNeutral$105.00 ➝ $110.00Low
1/6/2023Morgan StanleyBoost TargetOverweight$117.00 ➝ $133.00Low
1/4/2023BarclaysBoost Target$114.00 ➝ $122.00Low
12/12/2022CitigroupBoost TargetBuy$114.00 ➝ $125.00Low
10/26/2022MizuhoInitiated CoverageNeutral$105.00Low
10/21/2022Raymond JamesLower TargetOutperform$117.00 ➝ $109.00Low
10/20/2022Evercore ISILower Target$110.00Low
10/20/2022Morgan StanleyLower TargetOverweight$126.00 ➝ $117.00Low
10/20/2022Royal Bank of CanadaLower TargetOutperform$132.00 ➝ $126.00Low
10/17/2022BarclaysInitiated CoverageOverweight$118.00Low
10/17/2022BTIG ResearchLower TargetBuy$126.00 ➝ $123.00Low
10/12/2022Jefferies Financial GroupInitiated CoverageHold$110.00Low
10/11/2022Morgan StanleyLower TargetOverweight$132.00 ➝ $126.00Low
10/10/2022Wells Fargo & CompanyLower TargetOverweight$150.00 ➝ $140.00Low
10/5/2022CitigroupLower Target$123.00 ➝ $117.00Low
8/25/2022Erste Group BankDowngradeBuy ➝ HoldLow
7/27/2022UBS GroupLower TargetBuy$142.00 ➝ $128.00Low
7/22/2022Evercore ISILower Target$112.00Low
7/21/2022Morgan StanleyLower TargetOverweight$134.00 ➝ $132.00Low
7/21/2022Royal Bank of CanadaLower Target$143.00 ➝ $132.00Low
7/21/2022CitigroupLower TargetBuy$125.00 ➝ $123.00Low
7/18/2022BTIG ResearchLower TargetBuy$130.00 ➝ $126.00Low
7/18/2022Stifel NicolausLower Target$136.00 ➝ $126.00Low
7/15/2022Morgan StanleyLower TargetOverweight$145.00 ➝ $134.00Low
7/13/2022CowenLower Target$150.00 ➝ $130.00Low
7/13/2022CowenLower Target$150.00 ➝ $130.00Low
7/5/2022Wolfe ResearchInitiated CoverageUnderperformN/A
6/24/2022BTIG ResearchLower TargetBuy$140.00 ➝ $130.00Low
6/7/2022Morgan StanleyLower TargetOverweight$151.00 ➝ $145.00Medium
5/17/2022CitigroupLower TargetNA$154.00 ➝ $125.00N/A
4/21/2022Royal Bank of CanadaLower TargetOutperform$146.00 ➝ $143.00Low
4/21/2022Raymond JamesLower TargetOutperform$143.00 ➝ $135.00Low
4/8/2022Wells Fargo & CompanyLower TargetOverweight$155.00 ➝ $150.00Medium
3/1/2022Bank of AmericaInitiated CoverageBuy ➝ Buy$140.00Medium
1/27/2022Credit Suisse GroupBoost TargetOutperform$138.00 ➝ $139.00Low
1/27/2022UBS GroupBoost TargetBuy ➝ Buy$138.00 ➝ $142.00Low
1/27/2022Morgan StanleyLower TargetOverweight$157.00 ➝ $151.00Low
1/27/2022Raymond JamesLower TargetOutperform$150.00 ➝ $143.00Low
1/26/2022BTIG ResearchLower Target$143.00 ➝ $138.00Low
1/10/2022CowenBoost Target$140.00 ➝ $150.00Medium
1/7/2022Morgan StanleyBoost TargetOverweight$146.00 ➝ $157.00Low
12/23/2021Raymond JamesLower Target$150.00 ➝ $134.00Low
12/22/2021Raymond JamesBoost TargetOutperform$134.00 ➝ $150.00High
12/9/2021Royal Bank of CanadaInitiated CoverageOutperform$146.00Low
10/27/2021Atlantic SecuritiesUpgradeNeutral ➝ Overweight$144.00High
10/21/2021Morgan StanleyBoost TargetOverweight$136.00 ➝ $146.00High
10/21/2021SVB LeerinkReiterated RatingMarket Perform$128.00 ➝ $140.00High
10/21/2021Raymond JamesBoost TargetPositive ➝ Outperform$128.00 ➝ $134.00Medium
10/14/2021Redburn PartnersInitiated CoverageNeutral$103.13 ➝ $132.28Low
10/8/2021CowenReiterated RatingBuy$140.00Medium
10/1/2021CitigroupBoost TargetBuy$135.00 ➝ $140.00Medium
8/31/2021BTIG ResearchBoost TargetBuy$126.00 ➝ $136.00Low
8/23/2021CowenBoost TargetPositive ➝ Outperform$125.00 ➝ $140.00Medium
7/23/2021Morgan StanleyBoost TargetOverweight$126.00 ➝ $136.00Low
7/23/2021Credit Suisse GroupBoost TargetOutperform$120.00 ➝ $130.00Medium
7/23/2021Raymond JamesBoost TargetOutperform$116.00 ➝ $128.00Medium
7/20/2021SVB LeerinkBoost TargetMarket Perform$115.00 ➝ $128.00Low
7/12/2021Wells Fargo & CompanyBoost TargetMarket Perform ➝ Overweight$125.00 ➝ $135.00Low
6/2/2021BTIG ResearchLower TargetBuy$140.00 ➝ $120.00Medium
6/2/2021Credit Suisse GroupLower TargetOutperform$133.00 ➝ $120.00Medium
6/2/2021BarclaysLower TargetOverweight$150.00 ➝ $125.00Medium
6/2/2021Wells Fargo & CompanyLower TargetOverweight$137.00 ➝ $125.00Medium
6/2/2021Raymond JamesLower TargetOutperform$130.00 ➝ $116.00Medium
6/2/2021Morgan StanleyLower TargetOverweight$140.00 ➝ $126.00Medium
6/2/2021CitigroupReiterated RatingBuy$138.00 ➝ $125.00Medium
5/24/2021BarclaysInitiated CoverageOverweight$150.00Medium
4/21/2021Morgan StanleyBoost TargetOverweight$136.00 ➝ $140.00Medium
4/20/2021William BlairReiterated RatingOutperformLow
4/15/2021Atlantic SecuritiesInitiated CoverageNeutral$122.00High
3/11/2021Raymond JamesBoost TargetOutperform$126.00 ➝ $130.00Low
1/28/2021Wells Fargo & CompanyBoost Target$128.00 ➝ $137.00Medium
1/28/2021CowenBoost TargetOutperform$113.00 ➝ $140.00Medium
1/28/2021Credit Suisse GroupBoost TargetOutperform$118.00 ➝ $130.00High
1/28/2021Morgan StanleyBoost TargetOverweight$126.00 ➝ $136.00High
1/28/2021SVB LeerinkBoost TargetMarket Perform$115.00 ➝ $128.00High
1/28/2021Raymond JamesBoost TargetOutperform$114.00 ➝ $126.00High
1/28/2021BTIG ResearchUpgradeNeutral ➝ Buy$140.00High
12/15/2020Morgan StanleyBoost TargetOverweight$121.00 ➝ $126.00Low
11/19/2020Morgan StanleyBoost TargetOverweight$117.00 ➝ $121.00Low
10/22/2020Jefferies Financial GroupBoost TargetBuy$113.00 ➝ $123.00High
10/22/2020Credit Suisse GroupLower TargetOutperform$136.00 ➝ $118.00High
10/22/2020Raymond JamesBoost TargetMarket Perform ➝ Outperform$102.00 ➝ $114.00High
10/22/2020Morgan StanleyBoost TargetOverweight$112.00 ➝ $117.00High
10/22/2020SVB LeerinkBoost TargetPositive ➝ Market Perform$110.00 ➝ $115.00High
10/9/2020JPMorgan Chase & Co.Boost TargetOverweight$110.00 ➝ $125.00Low
10/7/2020Wells Fargo & CompanyBoost TargetOverweight$120.00 ➝ $122.00Low
9/11/2020Wolfe ResearchInitiated CoverageOutperform$124.00Low
9/2/2020The Goldman Sachs GroupSet TargetSell$94.00Low
8/31/2020Credit Suisse GroupBoost TargetOutperform$109.00 ➝ $136.00Low
8/28/2020CitigroupBoost TargetBuy$110.00 ➝ $130.00High
8/27/2020BTIG ResearchReiterated RatingHoldHigh
8/27/2020The Goldman Sachs GroupSet TargetSell$94.00Medium
8/27/2020Wells Fargo & CompanyBoost Target$107.00 ➝ $115.00Medium
8/27/2020Stifel NicolausBoost TargetBuy$108.00 ➝ $115.00Low
8/27/2020Morgan StanleyBoost TargetOverweight$106.00 ➝ $112.00Medium
7/23/2020ArgusBoost Target$110.00 ➝ $125.00Low
7/20/2020Bank of AmericaBoost TargetBuy$95.00 ➝ $110.00Medium
7/17/2020SVB LeerinkBoost TargetMarket Perform$97.00 ➝ $110.00High
7/17/2020Morgan StanleyBoost TargetOverweight$100.00 ➝ $106.00High
7/17/2020Credit Suisse GroupBoost TargetOutperform$106.00 ➝ $109.00High
7/17/2020CitigroupBoost TargetBuy$109.00 ➝ $110.00Medium
7/9/2020Wells Fargo & CompanyReiterated RatingBuy$107.00Low
6/25/2020Morgan StanleyLower TargetOverweight$108.00 ➝ $100.00High
5/31/2020The Goldman Sachs GroupDowngradeNeutral ➝ Sell$84.00Medium
5/22/2020Credit Suisse GroupReiterated RatingBuy$106.00Low
4/20/2020BarclaysBoost TargetOverweight$92.00 ➝ $100.00Medium
4/17/2020UBS GroupBoost TargetBuy$105.00 ➝ $109.00Low
4/17/2020JPMorgan Chase & Co.Boost TargetOverweight$88.00 ➝ $98.00Low
4/17/2020Stifel NicolausBoost Target$85.00 ➝ $108.00Low
4/17/2020Credit Suisse GroupBoost TargetOutperform$95.00 ➝ $106.00Medium
4/17/2020Raymond JamesBoost TargetOverweight ➝ Outperform$92.00 ➝ $102.00Low
4/17/2020CitigroupBoost TargetBuy$87.00 ➝ $109.00Medium
4/17/2020Wells Fargo & CompanyBoost TargetOverweight$95.00 ➝ $107.00Medium
4/16/2020BTIG ResearchReiterated RatingHoldLow
4/16/2020CfraBoost TargetBuy$99.00 ➝ $101.00Low
4/9/2020Wells Fargo & CompanyBoost TargetOverweight$92.00 ➝ $95.00Medium
4/9/2020Raymond JamesLower TargetOutperform$99.00 ➝ $92.00Medium
4/8/2020Wells Fargo & CompanyReiterated RatingBuyMedium
4/8/2020SVB LeerinkLower TargetMarket Perform$102.00 ➝ $93.00High
4/3/2020JPMorgan Chase & Co.Lower TargetOverweight$101.00 ➝ $88.00Low
3/30/2020Wells Fargo & CompanyReiterated RatingBuyMedium
3/27/2020CitigroupLower TargetBuy$96.00 ➝ $87.00Medium
3/27/2020Morgan StanleyLower TargetOverweight$101.00 ➝ $96.00Medium
3/6/2020Credit Suisse GroupLower TargetOutperform$104.00 ➝ $94.00High
3/4/2020CitigroupInitiated CoverageBuy$96.00Medium
2/12/2020The Goldman Sachs GroupInitiated CoverageNeutral$96.00Low
2/6/2020BTIG ResearchReiterated RatingHoldLow
1/23/2020JPMorgan Chase & Co.Lower Target$96.00 ➝ $101.00Low
1/23/2020UBS GroupBoost TargetBuy$99.00 ➝ $105.00Low
1/23/2020Wells Fargo & CompanyBoost TargetOverweight$97.00 ➝ $103.00Medium
1/23/2020Raymond JamesBoost TargetOutperform$90.00 ➝ $99.00Medium
1/23/2020Stifel NicolausBoost TargetBuy$95.00 ➝ $104.00Medium
1/2/2020CitigroupDowngradeNeutral ➝ SellHigh
1/2/2020Evercore ISIDowngradeOutperform ➝ In-LineHigh
1/2/2020GuggenheimDowngradeBuy ➝ NeutralMedium
12/17/2019Morgan StanleyBoost TargetOverweight$93.00 ➝ $101.00Medium
10/17/2019William BlairReiterated RatingUnderperformLow
10/17/2019Credit Suisse GroupBoost TargetOutperform$95.00 ➝ $98.00Low
10/14/2019Raymond JamesLower TargetOutperform$93.00 ➝ $90.00Low
7/18/2019Jefferies Financial GroupBoost TargetBuy$80.00 ➝ $98.00Medium
7/18/2019CowenBoost TargetOutperform$86.00 ➝ $95.00High
7/18/2019Raymond JamesBoost TargetOutperform$87.00 ➝ $93.00Medium
7/18/2019BMO Capital MarketsBoost TargetOutperform$87.00 ➝ $94.00Medium
7/16/2019Morgan StanleyBoost TargetOverweight$85.00 ➝ $93.00Low
6/13/2019Bank of AmericaReiterated RatingBuy$81.00Low
6/13/2019Wells Fargo & CompanyBoost TargetOutperform$89.00 ➝ $91.00Low
4/18/2019William BlairReiterated RatingOutperformN/A
(Data available from 4/16/2019 forward)

News Sentiment Rating

0.89 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 18 very positive mentions
  • 18 positive mentions
  • 4 negative mentions
  • 5 very negative mentions
9/18/2023
  • 36 very positive mentions
  • 32 positive mentions
  • 9 negative mentions
  • 2 very negative mentions
10/18/2023
  • 26 very positive mentions
  • 34 positive mentions
  • 7 negative mentions
  • 4 very negative mentions
11/17/2023
  • 26 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/17/2023
  • 34 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/16/2024
  • 65 very positive mentions
  • 48 positive mentions
  • 4 negative mentions
  • 1 very negative mentions
2/15/2024
  • 48 very positive mentions
  • 25 positive mentions
  • 5 negative mentions
  • 1 very negative mentions
3/16/2024
  • 48 very positive mentions
  • 32 positive mentions
  • 3 negative mentions
  • 5 very negative mentions
4/15/2024

Current Sentiment

  • 48 very positive mentions
  • 32 positive mentions
  • 3 negative mentions
  • 5 very negative mentions

Recent Stories by Sentiment

Abbott Laboratories logo
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.
Read More

Today's Range

Now: $108.89
Low: $108.83
High: $110.89

50 Day Range

MA: $114.67
Low: $108.89
High: $120.98

52 Week Range

Now: $108.89
Low: $89.67
High: $121.64

Volume

4,594,295 shs

Average Volume

5,567,693 shs

Market Capitalization

$188.94 billion

P/E Ratio

33.40

Dividend Yield

2.02%

Beta

0.74

Frequently Asked Questions

What sell-side analysts currently cover shares of Abbott Laboratories?

The following sell-side analysts have issued reports on Abbott Laboratories in the last year: Barclays PLC, BTIG Research, Citigroup Inc., Evercore ISI, Jefferies Financial Group Inc., JPMorgan Chase & Co., Mizuho, Morgan Stanley, Raymond James, Royal Bank of Canada, Sanford C. Bernstein, StockNews.com, TheStreet, UBS Group AG, Wells Fargo & Company, and Wolfe Research.
View the latest analyst ratings for ABT.

What is the current price target for Abbott Laboratories?

14 Wall Street analysts have set twelve-month price targets for Abbott Laboratories in the last year. Their average twelve-month price target is $122.14, suggesting a possible upside of 12.2%. Barclays PLC has the highest price target set, predicting ABT will reach $141.00 in the next twelve months. Wolfe Research has the lowest price target set, forecasting a price of $103.00 for Abbott Laboratories in the next year.
View the latest price targets for ABT.

What is the current consensus analyst rating for Abbott Laboratories?

Abbott Laboratories currently has 3 hold ratings and 10 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for ABT.

What other companies compete with Abbott Laboratories?

Other companies that are similar to Abbott Laboratories include Novartis, AstraZeneca, Pfizer, Sanofi and Vertex Pharmaceuticals. Learn More about companies similar to Abbott Laboratories.

How do I contact Abbott Laboratories' investor relations team?

Abbott Laboratories' physical mailing address is 100 ABBOTT PARK ROAD D-322 AP6D, ABBOTT PARK IL, 60064. The healthcare product maker's listed phone number is (224) 667-6100. The official website for Abbott Laboratories is www.abbott.com. Learn More about contacing Abbott Laboratories investor relations.